Mike Kratky
Stock Analyst at Leerink Partners
(3.49)
# 883
Out of 4,944 analysts
29
Total ratings
52.38%
Success rate
30.28%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Initiates: Outperform | $118 | $102.64 | +14.96% | 1 | Jun 16, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $92.08 | +19.46% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $14.22 | +96.91% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $12.81 | -6.32% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $80.17 | +8.52% | 2 | Oct 25, 2024 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $167 → $197 | $83.93 | +134.72% | 2 | Sep 10, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $248.55 | +5.81% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $11.11 | +305.22% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $9.13 | +140.96% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $309.63 | -40.57% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $36.54 | +14.94% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $478.19 | -28.48% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $76.93 | -2.51% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $38.60 | -4.15% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $14.16 | -36.44% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $3.28 | +1,423.51% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.68 | +2,578.57% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $359.00 | -12.26% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $39.87 | -22.25% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $15.20 | -7.89% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $17.97 | +122.59% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $392 → $384 | $10.90 | +3,422.94% | 1 | Aug 11, 2022 |
Boston Scientific
Jun 16, 2025
Initiates: Outperform
Price Target: $118
Current: $102.64
Upside: +14.96%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $92.08
Upside: +19.46%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $14.22
Upside: +96.91%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $12.81
Upside: -6.32%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $80.17
Upside: +8.52%
Inspire Medical Systems
Sep 10, 2024
Maintains: Market Perform
Price Target: $167 → $197
Current: $83.93
Upside: +134.72%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $248.55
Upside: +5.81%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $11.11
Upside: +305.22%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $9.13
Upside: +140.96%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $309.63
Upside: -40.57%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $36.54
Upside: +14.94%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $478.19
Upside: -28.48%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $76.93
Upside: -2.51%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $38.60
Upside: -4.15%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $14.16
Upside: -36.44%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $3.28
Upside: +1,423.51%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.68
Upside: +2,578.57%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $359.00
Upside: -12.26%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $39.87
Upside: -22.25%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $15.20
Upside: -7.89%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $17.97
Upside: +122.59%
Aug 11, 2022
Maintains: Outperform
Price Target: $392 → $384
Current: $10.90
Upside: +3,422.94%